Influence of Chronic Kidney Disease on Platelet Reactivity Response to Clopidogrel and Ticagrelor
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27031359 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von André Franci und 10 weiteren Autor:innen. Beteiligte Einrichtung: Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo CEP 05403-000, Brazil. Hauptthemen laut MEDLINE: Blood Platelets, Clopidogrel, Platelet Activation, Platelet Aggregation Inhibitors. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
High platelet reactivity (HPR) in patients with coronary artery disease receiving P2Y12 inhibitors increases ischemic risk. Chronic kidney disease (CKD) is an established contributor to HPR during clopidogrel therapy. The objective of the study was to assess whether CKD influences platelet reactivity (PR) in patients treated with clopidogrel or ticagrelor. This double-blind, double-dummy study enrolled 106 stable patients more than one year after an acute coronary syndrome, with or without CKD. Participants were matched by age and sex and randomized to clopidogrel or ticagrelor. PR was measured using the VerifyNow™ P2Y12 assay, and HPR was defined as P2Y12 reaction units (PRU) ≥ 208. Median glomerular filtration rates were 80 mL/min/1.73 m2 in non-CKD patients and 41 mL/min/1.73 m2 in CKD patients (p < 0.01). Ticagrelor produced similarly low PR in both groups (36 vs. 35 PRU; p = 0.61). Clopidogrel resulted in a numerically higher PR in CKD patients (209 vs. 180 PRU; p = 0.07). The magnitude of PR reduction with ticagrelor relative to clopidogrel was greater in CKD patients (p-interaction = 0.09). HPR was markedly more common with clopidogrel, particularly in CKD (difference 37%; adjusted OR 4.42; p = 0.01). In conclusion, CKD significantly impairs clopidogrel responsiveness but does not affect ticagrelor, resulting in a greater relative advantage of ticagrelor in patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo CEP 05403-000, Brazil.
- Centro de Cardiologia, Hospital Sírio-Libanês, Sao Paulo CEP 01308-050, Brazil.
- Hospital do Coracao do Brasil, Brasilia CEP 70390-000, Brazil.
- Royal College of Surgeons in Ireland, University of Medicine and Heath Sciences-Stephen's Green, D02 YN77 Dublin, Ireland.
ORCID-Profile: André Franci, Roberto Giraldez, Talia Dalçóquio, Aline Ferrari, Fernando Menezes, Danilo Sarti, Luciano Baracioli, José Nicolau
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Franci, A., Giraldez, R., Barbosa, C., Dalçóquio, T., Genestreti, P., Ferrari, A., Menezes, F., Furtado, R., Sarti, D., Baracioli, L., & Nicolau, J. (2026). Influence of Chronic Kidney Disease on Platelet Reactivity Response to Clopidogrel and Ticagrelor. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031359
Vancouver
Franci A, Giraldez R, Barbosa C, Dalçóquio T, Genestreti P, Ferrari A, et al. Influence of Chronic Kidney Disease on Platelet Reactivity Response to Clopidogrel and Ticagrelor. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031359
BibTeX
@article{Franci2026,
author = {Franci, André and Giraldez, Roberto and Barbosa, Carlos and Dalçóquio, Talia and Genestreti, Paulo and Ferrari, Aline and Menezes, Fernando and Furtado, Remo and Sarti, Danilo and Baracioli, Luciano and Nicolau, José},
title = {Influence of Chronic Kidney Disease on Platelet Reactivity Response to Clopidogrel and Ticagrelor},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27031359}
}
EUVIMED